BASEL, Switzerland, Feb. 4, 2004 (PRIMEZONE) -- Roche Group in 2003
-- Roche posts double-digit sales gains in core businesses, up
19% in local currencies (11% in CHF) to 29.0 billion CHF --
sustained strong growth in Q4 2003
-- Operating profit of core businesses before exceptional items
rises 25% in local currencies (17% in CHF) to 6.1 billion CHF,
operating profit margin up from 20.0% to 21.1%
-- Very robust gross cash flow (EBITDA) of 8.4 billion CHF from
core businesses, financial position strengthened further
-- Net income totals 3.1 billion CHF (following previous year's
net loss of 4.0 billion CHF) -- seventeenth dividend increase
in as many years
-- Further improvements to corporate governance, appointment of
independent lead director planned
-- Group publishes first separate Sustainability Report
-- Roche expects to outpace global market growth again in 2004,
operating profit margin of above 22% anticipated in 2005
Roche Pharmaceuticals in 2003
-- Thanks to organic growth and integration of Chugai,
Pharmaceuticals Division posts sales growth of 23% in local
currencies (14% in CHF), gains market share in all major
regions worldwide
-- Operating profit margin before exceptional items up 1.1
percentage points to 23.0%
-- Hepatitis C combination treatment Pegasys plus Copegus
exceeds expectations with sales of nearly 1 billion CHF
Roche Diagnostics in 2003
-- Diagnostics Division substantially ahead of world market as
sales grow by 8% in local currencies (3% in CHF)
-- Operating profit margin before exceptional items up 0.5
percentage points to 19.0%
-- Strategic boost from acquisitions of Disetronic and
Igen
Commenting on the full-year results for 2003, Roche Chairman and CEO Franz B. Humer said, "We are pleased to report that we achieved our ambitious goals in 2003. Together, our core pharmaceuticals and diagnostics businesses posted double-digit sales growth of 19% in local currencies, and both grew faster than their respective markets. Operating profit before exceptional items again grew faster than sales. It rose by 25% in local currencies to 6.1 billion Swiss francs. In addition, we strengthened Roche's financial position further and continued to enhance corporate governance. The good results achieved in 2003 confirm that our clear strategy of focus and innovation is on track and being successfully implemented. We firmly believe that long-term business success is possible only through economically, socially and environmentally sustainable value creation. Our new sustainability report underlines this commitment."
Key figures in millions of CHF
Roche Group
% change
2003 2002 in in local
CHF cur.
Sales 31,220 29,453 6 13
EBITDAb) 8,609 7,993 8 16
Operating profit before
exceptional items 6,268 5,448 15 24
Operating profit 5,592 1,335 319 350
Net income 3,069 -4,026 -- --
Research and development 4,766 4,257 12 21
Additions to property,
plant and equipment 2,265 2,044 11 17
Earnings per share
and non-voting
equity security, diluted (in CHF) 3.61 -4.80 -- --
Dividend per share and
non-voting equity security
(in CHF)c) 1.65 1.45 14 --
Employees 65,357 69,659 -6
Continuing businessesa)
% change
2003 2002 in in local
CHF cur.
Sales 28,960 26,066 11 19
EBITDAb) 8,390 7,532 11 20
Operating profit before
exceptional items 6,104 5,223 17 25
Operating profit 5,823 4,532 28 37
Net income 3,292 -1,052 -- --
Research and development 4,671 4,132 13 22
Additions to property,
plant and equipment 2,093 1,746 20 28
Earnings per share
and non-voting
equity security, diluted (in CHF) 3.87 -1.25 -- --
Dividend per share and
non-voting equity security
(in CHF)c) -- -- -- --
Employees 65,357 62,398 5
a) Continuing businesses includes the core pharmaceuticals and diagnostics businesses, together with treasury and other corporate activities. The Vitamins and Fine Chemicals Division is reported as a discontinuing business. b) EBITDA: Earnings before exceptional items and before interest and other financial income, tax, depreciation and amortisation, including impairment. This corresponds to operating profit before exceptional items and before depreciation and amortisation, including impairment. c) 2003 dividend as proposed by the Board of Directors.
Roche Group
In 2003 combined sales by Roche's core pharmaceuticals and diagnostics businesses totalled 29.0 billion Swiss francs, a year-on-year increase of 19% in local currencies (11% in CHF), with new and established Roche products contributing gains of around 12% and the integration of Chugai some 7%. Both divisions posted above-market growth, with pharmaceutical sales up 23% in local currencies (14% in CHF) and diagnostics sales up 8% in local currencies (3% in CHF).
Core businesses: substantial increases in operating profit and margin
Thanks to the strong sales growth and a reduction in other operating expenses, operating profit before exceptional items rose 25% in local currencies. Operating profit after exceptional items increased by an even stronger 37% in local currencies. The operating profit margin before exceptional items rose by 1.1 percentage points to 21.1% and after exceptional items by 2.7 percentage points to 20.1%.
Strong cash flow, major progress in finance
The Group's financial position was also strengthened in 2003, helped in particular by strong cash flow from operating activities and the proceeds from the sale of the Vitamins and Fine Chemicals Division to DSM. Roche's core pharmaceuticals and diagnostics businesses generated an impressive gross cash flow (EBITDA) of 8.4 billion Swiss francs. Group debt was substantially reduced and bank loans replaced by capital market bonds. The Group's net liquidity increased from 0.6 billion to 5.9 billion Swiss francs, while the equity ratio (including minority interests) improved from 40% to 49%.
Return to healthy net income level
In 2003 the Roche Group posted net income of 3.1 billion Swiss francs, or 3.3 billion francs for its core businesses, following the net loss recorded in 2002 under the impact of one-time charges. The consolidated financial statements for 2003 include Chugai's full-year results (versus three months for the year-earlier period) and the Vitamins and Fine Chemicals Division in the first nine months of the year, including the closing entries relating to the sale of the division.
Outlook optimistic
Roche expects both its pharmaceuticals and diagnostics businesses to grow faster than the global market in 2004. The Pharmaceuticals Division remains committed to achieving an operating profit margin approaching 26% before exceptional items by the end of 2004 (equivalent to the previously announced goal of an adjusted margin approaching 25%). The Diagnostics Division is expected to achieve its objective of an operating profit margin of around 23% before exceptional items in 2006 (equivalent to the previously announced goal of an adjusted margin of 20%). The Group anticipates an operating profit margin of above 22% in 2005.
Seventeenth dividend increase in as many years -- changes on the Board of Directors
Based on the strong gains in operating result and net income, the Board of Directors will ask the Annual General Meeting on 6 April 2004 to approve a dividend increase of 14%, to 1.65 Swiss francs per share and non-voting equity security.
As previously announced, Fritz Gerber, Andres F. Leuenberger and Henri B. Meier will be stepping down from the Board of Directors at this year's AGM. The Board will nominate Bruno Gehrig and Lodewijk J.R. de Vink as new members for election by the AGM. Subject to his election, Bruno Gehrig will assume the newly created function of Independent Lead Director. Before taking up his current position as chairman of the board of directors of Swiss Life Holding, Bruno Gehrig was vice-chairman of the governing board of the Swiss National Bank, which he joined in 1996. From 1992 to 1996 he was Professor of Business Economics at the University of St. Gallen. Lodewijk J.R. de Vink is a founding member and consultant of Blackstone Healthcare Partners. A past president of Schering International and former chairman, president and CEO of Warner-Lambert, Mr de Vink has very solid experience spanning many years in the pharmaceutical industry. The Board will also propose that the General Meeting elect KPMG as the new Group auditors and statutory auditors of Roche Holding Ltd.
Further improvements to corporate governance
The proposed changes to the Board of Directors mean that the majority of its members will be independent directors who can contribute substantial international experience and expertise. Other improvements to corporate governance at Roche include changes that facilitate comparison of the Group's results with those of other healthcare companies. As announced at the end of 2003, Roche is changing the presentation of its consolidated financial statements for the current and year-earlier periods to distinguish between continuing and discontinuing businesses. The expanded information in Roche's latest Annual Report includes details of the compensation paid to the Board of Directors and to each member of the Executive Committee.
Roche publishes first separate Sustainability Report
As a good corporate citizen, Roche has long accepted its responsibilities towards the environment and society. Its new Sustainability Report, which from now on will be published each year with the Annual Report, underscores this commitment. The Sustainability Report includes the Group's safety and environmental protection report, which used to be published separately each year. The new report details the main activities Roche is undertaking to promote sustainable development. In doing so, the company is observing the guidelines of the Global Reporting Initiative -- a body that unites the interests of various dialogue groups and works closely with agencies of the United Nations.
Pharmaceuticals Division
Double-digit growth in prescription drugs business
Key figures in millions % change % change as %
of CHF in CHF in local of sales
currencies
Sales 21,551 14 23 100
-- Roche worldwide
prescription group 19,781 14 23 92
-- Non-prescription medicines
(OTC) 1,770 12 17 8
EBITDA 6,542 13 21 30.4
Operating profit(a) 4,965 20 28 23.0
Research and development 3,946 14 25 18.3
Employees 46,625 4 -- --
(a)Before exceptional items
Sales by the Pharmaceuticals Division increased 23% in local currencies (14% in CHF) to 21,551 million Swiss francs. Even without the newly integrated Chugai, sales grew faster than the global market, with new and established Roche products accounting for over half of the gains (+14% in local currencies). Operating profit before exceptional items rose even faster than sales, advancing 28% in local currencies (20% in CHF) to 4,965 million Swiss francs. Despite substantially higher expenditures on new drug launches and on the many highly promising projects in its development pipeline, the Pharmaceuticals Division posted another significant increase in profitability, recording an operating profit margin before exceptional items of 23.0%, a gain of 1.1 percentage points. EBITDA was up 21% in local currencies (13% in CHF) to 6,542 million Swiss francs. The EBITDA margin was comparable to that of 2002.
Prescription medicines continue to post strong growth
Sales of prescription medicines in 2003 totalled 19,781 million Swiss francs, a rise of 23% in local currencies (14% in CHF). Operating profit before exceptional items reached 4,698 million Swiss francs, and the operating profit margin, at 23.8%, was also up again for the year. EBITDA increased to 6,234 million Swiss francs, or 31.5% of sales. The division's oncology portfolio(1) continued to be a major contributor to growth, with sales rising 30%(2) to 6,078 million Swiss francs. Sales and market penetration of Pegasys and Copegus, a new combination treatment for hepatitis C, surpassed the division's high expectations. Fuzeon, Roche's novel HIV/AIDS therapy, has now been launched in 12 markets worldwide. CellCept and NeoRecormon posted accelerated growth, with both products experiencing double-digit gains in their respective indications. As expected, Roaccutan/Accutane experienced sales erosion due to generic competition.
Above-market growth in all regions
Roche's prescription medicines posted above-market sales growth in all key regions. Thanks to strong sales by both Genentech and Roche, sales in North America increased by 20%, significantly outpacing the market. In Europe prescription drug sales accelerated in the double-digit range. The very strong sales increase recorded in the relatively sluggish Japanese market can be ascribed mainly to the consolidation of Chugai since 1 October 2002 and to above-average underlying organic growth. In Latin America sales returned to growth in a still-declining market. In rapidly developing markets from Eastern Europe to China, Roche has been growing very quickly and is strongly positioned as an industry leader.
Oncology -- Roche extends its market lead
In 2003 Roche strengthened its position as the world's number-one oncology company, with more than 6 billion Swiss francs in sales and a 30% growth rate. MabThera/Rituxan, for non-Hodgkin's lymphoma (NHL), achieved sales of 2.8 billion Swiss francs (+34%). Trial data announced in December showed that MabThera/Rituxan in combination with chemotherapy also represents a major clinical advance in the first-line treatment of indolent lymphoma. These data are expected to result in an expanded indication, potentially doubling the number of patients with indolent NHL who could benefit from treatment with MabThera/Rituxan. A regulatory filing for the combination was submitted to the EU authorities in January 2004. Herceptin sales rose 27%. A recent study has shown that the combination of Herceptin and Taxotere significantly improves patient survival compared with Taxotere alone. Based on these positive results, Roche has filed a marketing application for the Herceptin-Taxotere combination in the European Union. Roche expects the filing to be approved in 2004. Xeloda sales continued their strong upward trend, growing by 29%. This tumour-activated oral chemotherapeutic agent is used to treat breast and colorectal cancers. Xeloda was approved for the treatment of breast cancer in Japan. Sales of Kytril, an anti-emetic used in patients who are receiving chemotherapy or radiation therapy or who have undergone surgery, were up 7%. Thanks to its highly competitive profile, it recaptured market share in a fiercely contested segment.
Anemia -- strong growth
Combined sales of NeoRecormon and Epogin -- the leading products for the treatment of renal anemia in Europe and Japan, respectively -- rose 77%. NeoRecormon alone posted an impressive 30% increase in sales and achieved significant market share gains in Europe, where the regulatory authorities approved a new regimen in April for dialysis patients with stable hemoglobin levels. The use of this medicine in oncology continues to rise. A marketing application for a new, easy-to-use NeoRecormon formulation for once-weekly treatment of anemic patients with lymphoid malignancies was recently submitted to the EU authorities.
Transplantation -- sales of leading immunosuppressant in the US accelerate
Sales growth for Roche's immunosuppressive agent CellCept, the top-selling branded product in the United States for preventing organ rejection, accelerated to a rate of 27%. Combined sales of Valcyte and Cymevene grew 6%. Because of its potency and simple dosing schedule, Valcyte is increasingly the medicine of choice for preventing and treating cytomegalovirus infections (e.g. CMV retinitis). Initially approved for use in HIV-infected patients co-infected with CMV, the product gained important approvals last year in the European Union and the United States for use in solid organ transplant patients with CMV infections.
Virology -- exceptional gains in hepatitis C segment
Sales of Pegasys and Copegus, Roche's new drug combination for hepatitis C, totalled 942 million Swiss francs. In December Pegasys accounted for over 50% of total US interferon prescriptions for hepatitis C. Pegasys and Copegus are available for the treatment of hepatitis C in more than 80 countries. In October Pegasys monotherapy was approved in Japan, completing the regulatory approval process in all major markets worldwide. Fuzeon, the world's first fusion inhibitor, is being rolled out for HIV. The product belongs to the first new class of anti-HIV treatments in seven years and is the first and only drug that blocks the virus before it enters host cells. Fuzeon is currently available in 12 countries, and further important launches are expected in the near future. Sales totalled 49 million Swiss francs. Roche and its partner Trimeris are actively working to accelerate the uptake of Fuzeon in the US market. Combined sales of the protease inhibitors Viracept, Invirase and Fortovase declined by 11%. Viracept remains under pressure from competitor products and was also affected last year by additional price reductions in important markets. Sales of Tamiflu were up sharply, increasing by 184%, due to the severe 2002/2003 flu season in Japan and an early start to the 2003/2004 flu season in the United States.
Other major products -- Rocephin sales remain stable
While Xenical remained the leading weight management medicine in 2003, sales declined by 13% in line with market trends. In December 2003 the US Food and Drug Administration (FDA) approved labelling for the use of Xenical in the management of obesity in patients aged 12 to 16 years. Sales of Dilatrend, a beta blocking agent for hypertension, chronic heart failure and coronary artery disease, continued to rise, advancing 19% for the year. Well established in hypertension and coronary heart disease, Dilatrend benefited in late 2003 from new clinical data from the COMET study. Roche expects sales to decline in 2004, as Dilatrend will be going off patent in several major European markets at the beginning of April. Roche's new bisphosphonate, Bonviva/Boniva (ibandronate), was approved by the FDA in May 2003 for the treatment and prevention of osteoporosis in postmenopausal women and received a positive opinion for use in the same indication from the European Union's Committee for Proprietary Medicinal Products (CPMP) in October. Based on very encouraging phase III trial data, a supplemental filing for a simpler, more convenient dosage regimen will be submitted in 2004. Overall sales of Rocephin remained stable. Because of the early flu season in the United States and Japan sales in these markets rose by a substantial 7% and 14%, respectively, compensating for continued generic erosion in Europe, especially in France and Germany. Demand is expected to remain strong in the United States, where the product will continue to be protected by patent until 2005. Sales of Roaccutan/Accutane, for severe acne, fell 37%. The decline was largely due to the market entry of competing generics in the United States and Europe.
Research and development -- substantial number of new products expected
Roche's research and development pipeline is currently very strong, with 61 new molecular entities (NMEs), including five opt-in opportunities. The quality of the portfolio has steadily improved over the past three years. Roche is currently pursuing 125 research projects spanning seven therapeutic areas and 60 development projects in ten therapeutic areas. Results from a phase III trial with the late-stage cancer drug Avastin showed a 30% increase in survival duration in patients who received Avastin plus chemotherapy as first-line treatment for metastatic colorectal cancer. An application for approval of Avastin was filed in the United States in September and has been designated for priority review by the FDA; approval is expected in the first quarter of 2004. An EU filing was submitted in December. A monotherapy trial with Tarceva in pre-treated lung cancer patients is proceeding as planned, with results expected in the first quarter of 2004. Development of the innovative anemia treatment CERA for worldwide use in anemic patients with cancer or renal disease is moving ahead as planned. Phase III studies in renal patients are scheduled to start early in 2004, and phase III trials in cancer patients are due to start by the end of the year.
Roche Consumer Health -- strong organic growth
In 2003 sales of non-prescription (OTC) medicines, including sales by Chugai in Japan, grew 17% in local currencies (12% in CHF) to 1,770 million Swiss francs. Roche Consumer Health (RCH) achieved strong organic growth; excluding Chugai, sales increased by 5%. Solid sales growth was reported in almost all markets, but especially in the Asia-Pacific region and Eastern Europe. RCH's ten top-selling brands posted growth of 10%, with the strongest contributions coming from Bepanthen, Redoxon and Aleve. Chugai's OTC sales were in line with expectations. Operating profit from the OTC business totalled 267 million Swiss francs before exceptional items, a gain of 12% in local currencies (9% in CHF) over the previous year. The operating profit margin decreased slightly, to 15.1% before exceptional items, due to the lower profitability of Chugai's OTC business and investments to develop Xenical (orlistat) as an OTC product.
Diagnostics Division Market leadership extended
Key figures in millions % change % change as %
of CHF in CHF in local of sales
currencies
Sales 7,409 3 8 100
-- Diabetes Care 2,695 9 15 36
-- Near Patient Testing 548 -7 -2 7
-- Centralized Diagnostics 2,634 2 6 36
-- Molecular Diagnostics 1,024 5 13 14
-- Applied Science 508 -11 -6 7
EBITDA 2,111 6 12 28.5
Operating profit(a) 1,405 6 13 19.0
Research and development 724 7 11 9.8
Employees 18,302 7 -- --
(a)Before exceptional items
Sales by the Diagnostics Division in 2003 totalled 7,409 million Swiss francs, a year-on-year increase of 8% in local currencies (3% in CHF). Roche Diagnostics thus grew twice as fast as the global in-vitro diagnostics market. Profitability measures also continued to improve. Operating profit before exceptional items was up 13% in local currencies (6% in CHF) to 1,405 million Swiss francs, with EBITDA rising 12% in local currencies (6% in CHF) to 2,111 million Swiss francs. The operating profit margin was up 0.5 percentage points to 19.0%, and the EBITDA margin advanced 0.9 percentage points to 28.5%. The division's most profitable and fastest-growing businesses -- Diabetes Care, Molecular Diagnostics and immunochemistry -- were the main contributors to this strong performance. Further growth was generated by a large number of attractive new products.
Regions -- above-average growth worldwide
Roche Diagnostics recorded significant sales gains in all regions, despite weak or negative growth in the world's major diagnostics markets. Sales in North America were up 7%, double the market average. In Europe, a market characterised by healthcare budget restrictions, sales growth was 10%. Sales in Japan rose 3%, despite a decline in the market as a whole. In Asia-Pacific and Iberia/Latin America Roche Diagnostics expanded its market share with double-digit sales growth.
Diabetes Care -- integration of Disetronic on track
Roche Diabetes Care grew 15%, outpacing the market by a substantial margin as it further extended its leading position in blood glucose monitoring. In 2003 Diabetes Care expanded and optimised its portfolio of blood glucose monitoring systems. New versions of the proven Accu-Chek Advantage and Accu-Chek Active glucose meters posted good sales right from the start, as did a new test strip for Accu-Chek Compact; the new strip gives faster results from less blood. In addition, the roll-out of Accu-Chek Go, a novel and especially user-friendly glucose meter, started at the end of 2003. The acquisition of Disetronic, the world's second-largest supplier of insulin pumps, is an important strategic move. As a result of this transaction, which was finalised in May 2003, Roche now offers a comprehensive range of products for people with diabetes, from glucose monitoring and data management to insulin delivery. The integration of Disetronic's facilities is proceeding according to plan and has already been completed in most countries. Roche is working closely with the FDA to address the agency's concerns about Disetronic's production processes and documentation. The Group aims to resume pump sales in the US in the second half of 2004; reinspection by the FDA is expected to take place around the middle of the year.
Near Patient Testing -- steady market share gains in a variety of segments
Total sales by Roche Near Patient Testing decreased by 2% in 2003 due to streamlining of the product range early in the year (divestment of the OPTI systems and drugs-of-abuse testing businesses). On a comparable basis Near Patient Testing sales rose 6%. Worldwide sales of coagulation monitoring products increased by over 20%, with demand fuelled largely by the continuing trend to patient self-monitoring. Coagulation monitoring is another segment in which Roche Diagnostics is the clear market leader, with a market share of 95%. Roche is also steadily improving its market share in the Hospital Point of Care segment. Key factors behind the high growth in this segment in 2003 were the decision to refocus activities on the core business and strong sales of cardiac assays and OMNI blood gas analysers. In the Primary Care segment (compact systems for doctors' offices) the multiparameter systems of the Reflotron product line and Accutrend cholesterol testing products posted above-average growth. The rollout of a new generation of instruments offering standardised urinalysis met with a good market response.
Centralized Diagnostics -- acquisition of Igen gives Roche access to high-growth market
Sales by Roche Centralized Diagnostics rose 6%, fuelled by high demand for modular high-tech systems for diagnostic laboratories. Once again, the Elecsys immunochemistry product line posted double-digit gains. In 2003 Roche transferred its US hematology business back to its partner, Sysmex. Roche's agreements with Sysmex outside the US are unaffected by this move. Roche expects to complete its acquisition of US-based Igen, announced in July 2003, in mid-February 2004. This strategic move secures Roche's rights to the use of electrochemiluminescence (ECL) technology and also allows it to tap into new markets in one of the division's largest growth areas, immunochemistry. Since the acquisition was announced, Centralized Diagnostics has signed contracts for several large orders.
Molecular Diagnostics -- first pharmacogenomic DNA microarray launched
Sales of in-vitro diagnostic products by Roche Molecular Diagnostics grew by 21%, while sales of enzymes to industrial customers, which account for a relatively small percentage of revenues, declined. Growth in sales of blood screening tests and tests for sexually transmitted diseases was in the high double-digit range. In just eight weeks Molecular Diagnostics developed the first PCR-based research test to detect the virus that causes the respiratory disease SARS. In addition, it developed a highly automated test for screening donated blood for West Nile virus and other pathogens belonging to the Japanese encephalitis virus group. June saw the US launch, for research use, of AmpliChip CYP450, the world's first pharmacogenomic microarray. In future the new DNA chip-based test will help physicians select the appropriate medication and dosage. Roche is working to obtain approval in the United States and Europe for a clinical diagnostic version of the test in 2004. At the end of 2003 in the United States Roche launched a product that enables qualitative testing for human papilloma virus, initially for use by certain specialist laboratories. It plans to launch a clinical diagnostic version in early 2004. Cobas TaqMan 48 was launched in the United States in June and received EU marketing approval shortly thereafter. The system puts real-time PCR technology within the reach of small and medium-sized laboratories for the first time.
Applied Science -- numerous product launches
Sales by Roche Applied Science declined 6% due to the sluggish economic climate and a weak biotech market, especially in the United States. A number of important products for use in genomics were launched in 2003, including an updated version of the LightCycler system that offers greater versatility in research applications; MagNA Pure Compact, a compact benchtop instrument for fast, easy nucleic acid purification; and the new LightTyper, for single nucleotide polymorphism (SNP) analysis. In addition, Prionics Check LIA, a new, fully automated test that enables detection of BSE in slaughtered cattle, received marketing approval in Europe.
This Investor Update with all tables may be found at http://www.roche.com/home/investor/inv-news-updates.htm
Roche's 2003 Annual Report and -- for the first time -- the Sustainability Report 2003 as well as the presentations slides will be available at www.ir.roche.com as from 7:00 am CET.
Planned dates in 2004
-- 6 April: Annual General Meeting -- 21 April (tentative): first-quarter sales -- 21 July (tentative): half-year results
Disclaimer This release contains certain forward-looking statements. These forward-looking statements may be identified by words such as "believes", "expects", "anticipates", "projects", "intends", "should", "seeks", "estimates", "future" or similar expressions or by discussion of strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity or news coverage.
February 4, 2004
07.00 CET (Central European time)
Release will be e-mailed and posted on the Roche IR website. Presentation slides and the Annual Report 2003 will be posted on the Roche IR website http://ir.roche.com.
08.00 CET
Conference call will commence with presentations by senior management followed by a Q&A session. Participants will be: Dr. Erich Hunziker, Chief Financial Officer, William M. Burns, Head of the Pharmaceuticals Division and Heino von Prondzynski, Head of the Diagnostics Division Dr. Karl Mahler, Head of Investor Relations.
Analysts are invited to dial in to the conference using the following dial-in numbers: +41 91 610 5600 (Europe and ROW) or +44 207 107 06 11 (UK) or +1 866 291 4166 (USA).
Please dial into the conference call 10-15 minutes before the call is scheduled to start. You are also invited to download the presentation from the website. Alternatively you can follow the conference as a Live Audio Webcast through the Internet site http://ir.roche.com.
A replay of the conference call will be available one hour after the conference call, for 48 hours. Access is by dialing: +41 91 612 4330 (Europe), +44 207 866 4300 (UK) and +1 412 858 1440 (USA) and enter the conference ID 446 followed by the # sign. A replay of the webcast will be available on demand at http://ir.roche.com.
London, February 4, 2004
Due to flight schedules and restrictive new security guidelines practiced by some airlines the schedule for our London event had to be amended slightly. The conference will start 15 minutes earlier and will now begin at
15.15 London GMT (Greenwich Mean Time) / 16.15 CET
General Presentation and Q & A session will be held by: Dr. Franz B. Humer, Chief Executive Officer Dr. Erich Hunziker, Chief Financial Officer William M. Burns, Head of the Pharmaceuticals Division and Heino von Prondzynski, Head of the Diagnostics Division
Following the general presentation will be four break-out sessions, held simultaneously, covering the topics Strategy & Finance, Pharmaceuticals, Diagnostics and Accounting. The break-out sessions will be recorded and placed on the web within 48 hours.
For those who cannot attend in person, the presentation and Q&A session can be listened to via a telephone link (listen only mode, no live access to speakers). Please dial into the call 10-15 minutes before is scheduled to start. The Dial in numbers are: +41 91 610 5600 (Europe and ROW) or +44 207 107 06 11 (UK) or +1 866 291 4166 (USA).
You are also invited to download the presentation from the website. In addition, a Live Audio Webcast of the conference call will be available on our website http://ir.roche.com.
A replay of the conference call will be available one hour after the event, for 48 hours. Access is by dialing: +41 91 612 4330 (Europe), +44 207 866 4300 (UK) and +1 412 858 1440 (USA) and enter the Conference ID 511 followed by the # sign. A replay of the webcast will be available on demand at http://ir.roche.com.
New York, February 5, 2004
14.30 New York EST (Eastern Standard Time) / 20.30 CET
General Presentation and Q & A will be held by: Dr. Franz B. Humer, Chief Executive Officer, Dr. Erich Hunziker, Chief Financial Officer William M. Burns, Head of the Pharmaceuticals Division and Heino von Prondzynski, Head of the Diagnostics Division
Following the general presentation will be four break-out sessions (sessions will be repeated once) covering the topics Strategy & Finance, Pharmaceuticals, Diagnostics and Accounting. The break-out sessions will be recorded and placed on the web within 48 hours.
For those who cannot attend in person, the presentation and Q&A session can be listened to via a telephone link (listen only mode, no live access to speakers). Please dial into the call 10-15 minutes before is scheduled to start. The Dial in numbers are: +41 91 610 5600 (Europe and ROW) or +44 207 107 06 11 (UK) or +1 866 291 4166 (USA).
You are also invited to download the presentation from the website. In addition, a Live Audio Webcast of the conference call will be available on our website http://ir.roche.com.
A replay of the conference call will be available one hour after the event, for 48 hours. Access is by dialing: +41 91 612 4330 (Europe), +44 207 866 4300 (UK) and +1 412 858 1440 (USA) and enter the Conference ID 585 followed by the # sign. A replay of the webcast will be available on demand at http://ir.roche.com (1) Oncology portfolio: MabThera/Rituxan, Herceptin, Xeloda, Bondronat, Kytril, Furtulon, Neupogen, NeoRecormon (25%), Roferon-A (60%), Neutrogin, Picibanil. (2) All growth rates are based on local currencies.
The full report including tables can be downloaded from the following link: